NCT02736721: Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML) |
|
|
| Completed | 3 | 41 | Europe | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Myelogenous Leukemia, Chronic | 11/10 | 11/10 | | |
NCT01259856: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) |
|
|
| Completed | 3 | 168 | US, Europe | PEGASYS, Pegylated Interferon Alfa-2a, Hydroxyurea, Hydroxycarbamide, Aspirin, acetylsalicylic acid | Ronald Hoffman, Myeloproliferative Disorders-Research Consortium, National Cancer Institute (NCI), Roche Pharma AG | High Risk Polycythemia Vera, High Risk Essential Thrombocythemia | 06/17 | 06/17 | | |
NCT02829775 / 2004-002093-30: A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies |
|
|
| Completed | 2/3 | 9 | Canada, Europe, RoW | Pegylated Interferon Alfa-2a, Pegasys, Recombinant Interferon Alfa 2a, Roferon-A | Hoffmann-La Roche | Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma | 01/08 | 01/08 | | |
